The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma

Neuro-Oncology

Volumn 18, Issue 8, 2016, Pages 1129-1136

  Bernard Arnoux, F ^a   Lamure, M ^a   Ducray, F ^a   Aulagner, G ^b   Honnorat, J ^a   Armoiry, X ^c  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ DE LYON   (France)

^c CNRS   (France)

Author keywords

Brain tumor; Cost effectiveness analysis; Glioblastoma; Temozolomide; Tumor treating fields

Indexed keywords

ARTICLE; CANCER THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GLIOBLASTOMA; HEALTH CARE COST; LIFE EXPECTANCY; MATHEMATICAL MODEL; NEUROLOGICAL THERAPEUTIC DEVICE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; TUMOR TREATING FIELD THERAPY; UNCERTAINTY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE QUALITY; HUMAN; MAGNETOTHERAPY; MARKOV CHAIN; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; GLIOBLASTOMA; HUMANS; MAGNETIC FIELD THERAPY; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; STANDARD OF CARE;

EID: 84982162688     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now102     Document Type: Article

References (26)

1. Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12(7):725-735
2. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015;11(9):504-514
3. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis ESMO Guidelines Working Group. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii93-ii101
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996
5. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722
6. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708
7. Turner SG, Gergel T, Wu H, Lacroix M, Toms SA. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF-100A system. World J Surg Oncol. 2014;12:162
8. Stupp R, Taillibert S, Kanner A, et al. Tumor treating fields (TTFields): A novel treatment modality added to standard chemo-and radiotherapy in newly diagnosed glioblastoma-First report of the full dataset of the EF14 randomized phase III trial. JAMA. 2015;314(23):2535-2543
9. American Society of Clinical Oncology. Tumor Treating Fields Device Extends Glioblastoma Survival, but Cost Questions Raised. 2015. Available at http://am.asco.org/tumor-treatingfields-device-extends-glioblastoma-survival-cost-questionsraised (last accessed May 2016)
10. Haute Autorite de sante. Choices in Methods for Economic Evaluation: a methodological guide. 2012. Available at http:// www.hassante.fr/portail/upload/docs/application/pdf/2012-10/ choices-in-methods-for-economic-evaluation.pdf (last accessed May 2016)
11. Kovic B, Xie F. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015;33(20):2296-2302
12. Martikainen JA, Kivioja A, Hallinen T, Vihinen P. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. Pharmacoeconomics. 2005;23(8):803-815
13. Messali A, Hay JW, Villacorta R. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013;15(11): 1532-1542
14. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med. 1982;73(6):883-888
15. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med. 1982;73(6):889-897
16. Diebold G, Ducray F, Henaine AM, et al. Management of glioblastoma: comparison of clinical practices and costeffectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. J Clin Pharm Ther. 2014;39(6):642-648
17. Henaine AM, Paubel N, Ducray F, et al. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. J Clin Pharm Ther. 2016; 41(1):47-53
18. Esteves S, Alves M, Castel-Branco M, Stummer W. A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery. Neurosurgery. 2015;76(5): 552-562; discussion 562
19. Slof J, Diez Valle R, Galvan J. Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery. Neurologia. 2015;30(3):163-168
20. Lamers LM, Stupp R, van den Bent MJ, et al. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/ 22981 NCI-C CE3 Intergroup Study. Cancer. 2008;112(6): 1337-1344
21. Shankaran V, Ortendahl JD, Purdum AG, et al. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. Am J Clin Oncol. 2015 Sep 22. [Epub ahead of print]
22. Goldstein DA, Chen Q, Ayer T, et al. First-and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol. 2015;33(10):1112-1118
23. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011; 14(6):836-845
24. Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ. 2013; 16(2):202-212
25. Bohensky M, Pasupathi K, Gorelik A, Kim H, Harrison JP, Liew D. A Cost Effectiveness Analysis of Nivolumab Compared to Ipilimumab for the Treatment of Braf Wild-Type Advanced Melanoma in Australia. Value Health. 2015;18(7):A340
26. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii-iiv, ix-221